Role of GLP-1 receptor agonist in T2DM with Atherosclerotic Cardiovascular Disease- Dr PC Manoria at CSI Con 2021

Published On 2021-12-03 05:36 GMT   |   Update On 2021-12-06 11:53 GMT

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat type 2 Diabetes Mellitus. GLP-1 RAs drugs are very effective in lowering blood sugar levels. These Drugs are also beneficial in improving heart health and kidney function.In this Video, Dr. Prof. P.C. Manoria explains the Role of Glucagon-like peptide-1 receptor agonists in T2DM with Atherosclerotic Cardiovascular...

Login or Register to read the full article

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat type 2 Diabetes Mellitus. GLP-1 RAs drugs are very effective in lowering blood sugar levels. These Drugs are also beneficial in improving heart health and kidney function.

In this Video, Dr. Prof. P.C. Manoria explains the Role of Glucagon-like peptide-1 receptor agonists in T2DM with Atherosclerotic Cardiovascular Disease. The leading cause of death in People with Type 2 Diabetes Mellitus (T2DM ) is CVD. T2DM doubles the risk of CVD compared with adults without T2DM.



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News